Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its ...

Transposable elements play a significant role in regulating gene expression and genome architecture, influencing development, ...

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer cells. In some blood cancers, damaged genes trigger chaos in these DNA ...

Prime Medicine, Inc. ( PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST ...

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen ...

Researchers discovered that bowhead whales achieve extraordinary longevity and cancer resistance through highly efficient and ...

Long dismissed as evolutionary leftovers, segments of DNA once labeled “junk” may now offer a novel way to kill off deadly ...

Emerging trends in Healthcare Stocks include increasing adoption of gene therapies, advancements in precision medicine, and ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.